{"id":"W4414094800","doi":"10.1016/j.annonc.2025.08.3757","title":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Ipsen; Gilead Sciences; Bayer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; GlaxoSmithKline; Amgen","keywords":"Pembrolizumab; Adenoid cystic carcinoma; Phases of clinical research; Carcinoma; Melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009182558,0.00009487158,0.0002187696,0.0001489262,0.0000153732,0.000001927954,0.00003798537,0.0001050174,0.000001139974],"category_scores_gemma":[0.00001518116,0.00008325624,0.00000942886,0.0001844618,0.00007925789,0.000009249028,0.00002469985,0.00005552414,2.861582e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003815069,"about_ca_system_score_gemma":0.0001975043,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002726683,"about_ca_topic_score_gemma":0.002399038,"domain_scores_codex":[0.9992937,0.00007143347,0.0002199853,0.0002302232,0.00007932057,0.0001053406],"domain_scores_gemma":[0.9995598,0.00001492267,0.0001511635,0.0001188248,0.0001335038,0.00002174093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06902845,0.008611752,0.4553071,0.000141766,0.0002735657,0.000006073437,0.002439269,0.006870616,0.1272663,0.00005077487,0.0001222239,0.3298822],"study_design_scores_gemma":[0.08456781,0.06733524,0.7637867,0.0001917492,0.00003209343,0.000002056785,0.000724938,0.0002857889,0.082053,0.0000971948,0.0007084093,0.0002150368],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985824,0.0004514366,0.00001908666,0.00016147,0.00002880648,0.0006628876,0.000004132889,0.000002104814,0.00008773345],"genre_scores_gemma":[0.9994677,0.0002990726,0.00006737529,0.00006728814,0.000005733372,0.00004103104,0.00002380077,0.000007981718,0.00002003443],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3296671,"threshold_uncertainty_score":0.3395091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009787600156352473,"score_gpt":0.3268003003395209,"score_spread":0.3170127001831684,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}